Quant Business Cycle Fund
The scheme seeks to generate long-term capital appreciation by investing with focus on riding business cycles through allocation between sectors and stocks at different stages of business cycles.
Growthvine rating: 4/5 — ranked #34 of 179 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹16.38 (as of 2026-08-21) |
|---|
| AUM | ₹1,016 Cr |
|---|
| Expense ratio | 1.93% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ayusha Kumbhat |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| Sharpe ratio | 0.47 |
|---|
| Standard deviation | 20.70% |
|---|
| Max drawdown | -30.87% |
|---|
| Alpha | 1.68 |
|---|
| Beta | 1.2 |
|---|
Over 5 years, captured 77.6% of NIFTY Alpha 50's upside and 75.8% of its downside.
Market cap allocation
| Large cap | 46.8% |
|---|
| Mid cap | 39.0% |
|---|
| Small cap | 14.2% |
|---|
Concentration
| Top 5 holdings | 45.7% |
|---|
| Top 10 holdings | 73.6% |
|---|
| Total holdings | 18 |
|---|
Top holdings
- TREPS 03-Aug-2026 DEPO 10 — 21.4%
- Piramal Finance Limited — 9.6%
- Kotak Mahindra Bank Limited 25/08/2026 — 9.3%
- Adani Green Energy Limited — 9.2%
- Aurobindo Pharma Ltd. — 9.2%
- INDUS TOWERS LIMITED — 8.5%
- Tech Mahindra Limited — 7.0%
- Divis Laboratories Limited 25/08/2026 — 6.5%
- Adani Enterprises Ltd. — 4.9%
- Lloyds Metals and Energy Limited — 4.7%
Top sectors
- Derivatives — 27.4%
- Pharma & Biotech — 10.9%
- Finance & Investments — 9.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 4.8% | Q2 | #75 of 167 |
| 2025 | -6.5% | Q4 (Bottom) | #125 of 132 |
| 2024 | 19.2% | Q3 | #50 of 86 |